Innervace
Latest round
- Series A
Last raised
- Aug 2022
Total raised
- $10M
Investors
- 5
About Innervace
Based in New York, US, and founded in 2020 by Douglas Smith, and D., a University of Pennsylvania spinoff, is a company that develops and commercialize anatomical-based living implants for brain pathway reconstruction. In August 2022, Innervace, Inc. As of 2022, Nader Halim is the Chief Executive Officer (CEO) of the company. Innervace, Inc. is a regenerative therapy company that is developing technology that acts as pre-formed, anatomically inspired, implantable tissue pathways to replace lost connections in the brain caused by degeneration or injury. The company offers minimally invasive MRI (Magnetic resonance imaging) guided implantation with customizable length, dose, cell type, and cell source.
Who invested in Innervace
5 investors across 1 round
See all investors in Innervace
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 8, 2022
Amount
$10M
Investors
Questions about Innervace
Who invested in Innervace?
Innervace has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innervace raised?
Innervace has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Innervace last raise money?
Innervace's most recent round on record is a Series A, in Aug 2022.
What does Innervace do?
Based in New York, US, and founded in 2020 by Douglas Smith, and D.
Where is Innervace headquartered?
Innervace is headquartered in New York, US.
Which VCs invest in companies like Innervace?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Innervace's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Innervace? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.